Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.

    The EU Clinical Trials Register currently displays   41232   clinical trials with a EudraCT protocol, of which   6757   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools

    < Back to search results

    Print Download

    EudraCT Number:2006-005467-26
    Sponsor's Protocol Code Number:104RA203
    National Competent Authority:Belgium - FPS Health-DGM
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2007-02-14
    Trial results View results
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedBelgium - FPS Health-DGM
    A.2EudraCT number2006-005467-26
    A.3Full title of the trial
    A phase 2b, randomised, double-blind, placebo-controlled, multi-centre, dose-finding study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of BG9924 when given in combination with methotrexate to subjects with active Rheumatoid Arthritis who have had an inadequate response to anti-TNF therapy
    A.4.1Sponsor's protocol code number104RA203
    A.7Trial is part of a Paediatric Investigation Plan Information not present in EudraCT
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBiogen Idec Ltd
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing support
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisation
    B.5.2Functional name of contact point
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code BG9924
    D.3.4Pharmaceutical form Powder for solution for injection
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D. cell therapy medicinal product No
    D. therapy medical product No
    D. Engineered Product Information not present in EudraCT
    D. ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D. on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection
    D.8.4Route of administration of the placeboSubcutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Rheumatoid arthritis (RA)
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 9.1
    E.1.2Level PT
    E.1.2Classification code 10039073
    E.1.2Term Rheumatoid arthritis
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of the trial is to evaluate the efficacy of BG9924 when administered in combination with MTX to subjects with active RA who have had an inadequate response to anti-TNF therapy. The primary efficacy outcome measure is the proportion of subjects with ACR50 at week 14. To achieve ACR50 response, a 50% improvement compared to baseline is required for both swollen and tender joint counts, as well as 3 out of 5 additional parameters: subject's global assessment of disease activity, investigator's global assessment of disease activity, subject's assessment of pain, HAQ-DI and hsCRP or ESR.
    E.2.2Secondary objectives of the trial
    To assess the safety and tolerability of BG9924 in this patient population.
    To assess the PK and PD profile of BG9924 in this patient population.
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Study sites may choose to participate in an optional PK sub-study. Approximately 20 consenting subjects will have 6 additional visits following Visits 1 (Visits 1a and 1b), 3 (Visit 3a), and 8 (Visits 8a, 8b, and 8c). Blood samples for FACS analysis will also be taken from subjects participating in this sub-study.
    E.3Principal inclusion criteria
    Unless otherwise specified, to be eligible to participate in this study, candidates must meet the following eligibility criteria at Day 0 (Visit 1/Week 0):
    1.Must give written informed consent and any authorizations required by local law (e.g., Protected Health Information [PHI]).
    2.Aged 18 to 75 years old, inclusive, at the time of informed consent.
    3.Must have a diagnosis of adult onset RA according to the 1987 Revised American Rheumatism Association Criteria for the Classification of Rheumatoid Arthritis (Functional Class I–III) (Appendix A) for at least 6 months prior to Day 0.
    4.Must have been treated with, and be tolerating, MTX (>or=10 mg/week to <or=25 mg/week) for at least 3 months immediately prior to Day 0. The dose of MTX must be stable for at least 4 weeks prior to Day 0.
    5.Must have had an inadequate response to anti-TNF therapy (etanercept, infliximab, or adalimumab) due to inadequate efficacy or toxicity.
    6.Must have a Swollen Joint Count (SJC) >or=8 and a Tender Joint Count (TJC) >or=8 (66/68 joint count at Screening).
    7.Must have elevated hsCRP >or=≥1.5 times the upper limit of normal (ULN) or
    ESR ≥28 mm/hr at Screening.
    8.Must be willing to receive oral folate (>or=5 mg/week) for the duration of the study.
    E.4Principal exclusion criteria
    1.Subjects with body weight of <50kg
    2.Subjects with history of malignancy or carcinoma in situ (subjects with a history of excised or treated basal cell carcinoma are eligible to participate in this study)
    3.Subjects with mole or lesion currently undiagnosed, but suspicious for malignancy. Any suspicious skin lesion should be evaluated and excised by a dermatologist prior to inclusion in the study
    4.History of clinically significant (as determined by Investigator) cardiac, allergic, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal or hematologic insufficiency, or any major disease that could affect any of the efficacy assessments, in particular, joint pain and swelling (e.g. Parkinsons disease, cerebral palsy, diabetic neuropathy)
    5.Subjects with rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA (including but not limited to vasculitis, pulmonary fibrosis, or Felty's syndrome). Secondary Sjogren's syndrome or secondary limited cutaneous vasculitis within RA is permitted
    6.Serious local infection (e.g. cellulitis, abscess) or systemic infection (e.g. pneumonia, septicemia) within 3 months prior to D0 (V1/W0)
    7.History of recurrent infections requiring oral or parental anti-infective drug treatment
    8.Primary or secondary immunodeficiency (history of or currently active) including known history of HIV infection
    9.History of tuberculosis or positive purified protein derivative (PPD; positive Mantoux test defined as >or=10 mm of induration [size of raised lump, not redness], or eq. positive tuberculosis (TB) test result as per country clinical standards) during the screening period. When PPD induration is >or=5 mm, but <10 mm the subject is eligible for the study if they have had a negative chest x-ray during screening period. There must be no other clinical evidence of TB on physical examination of the subject. Note: Subjects who have had prior adequate prophylaxis treatment for latent TB with an appropriate course of isoniazid (INH) or equivalent, per country standards, are not excluded from study participation.
    10.Fever (body temp. >38°C) or symptomatic viral infection or bacterial infection within 2W prior to D0
    11.Receipt of live vaccine within 4W prior to D0
    12.Clinically significant chest x-ray abnormality at Screening (Note: chest x-ray is not required if one was performed within 3 months of D0 and was without clinical abnormality)
    13.Subjects with any laboratory test result at Screening considered clinically significant (as determined by Investigator) or
    o AST or ALT >1.5 times than ULN established by central laboratory
    o Platelet count <150,000/μL
    o Hemoglobin <8.5 g/dL
    o Neutrophils <1.5 x 10exp3/μL
    14.Positive for hepatitis C antibody or hepatitis B [HBsAg] at Screening
    15.Previous treatment with any anti-CD20 therapy (rituximab or ocrelizumab) or Campath (alemtuzumab) for the treatment of RA.
    16.If subjects have previously received cell-depleting therapies (including, but not
    limited to, anti-CD3, anti-CD4, anti-CD5, anti-CD11a, anti-CD19, anti-
    CD22, and/or BlyS/BAFF), relevant cell counts must have returned to normal
    17.Treatment with another IMP within the 3 months prior to D0 or within 5 half-lives of the agent, whichever is longer
    18.Previous exposure to BG9924
    19.Treatment with the following concomitant medications as
    indicated below:
    o Any oral steroid exceeding 10 mg/day of prednisone or equivalent
    administered within 4 weeks prior to Day 0 or any oral steroid
    ≤10 mg/day of prednisone or equivalent that was not administered at a
    stable dose for at least 4 weeks prior to Day 0.
    o Leflunomide administered within 8 weeks prior to Day 0 (if the subject has received 11 days of standard cholestyramine or activated charcoal washout, treatment with leflunomide may not be administered within 14 days prior to Day 0).
    o Cyclosporin A administered within 6 months prior to Day 0.
    o Azathioprine or 6-MP administered within 28 days prior to Day 0.
    o Hydroxychloroquine sulfate or sulfasalazine (or equivalents), or any other
    allowed concomitant DMARDs, administered at doses greater than the recommended therapeutic dose or not administered at a stable dose for 4 weeks prior to Day 0.
    o Any NSAIDS not at a stable dose for least 2W prior to D0
    o Intra-articular corticosteroid injections given within 4W prior to D0
    20.Subjects who underwent any surgical procedure, including bone/joint surgery/synovectomy (including joint fusion or replacement), within 12W prior to D0 or who are planning an unapproved (by BIIB) procedure within 24 WKS of D0
    21. 22. 23. 24. 25. 26. and 27, refer to the study protocol
    E.5 End points
    E.5.1Primary end point(s)
    The proportion of subjects with an ACR50 response at Week 14.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis Information not present in EudraCT
    E.6.2Prophylaxis Information not present in EudraCT
    E.6.3Therapy Information not present in EudraCT
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Information not present in EudraCT
    E.6.7Pharmacodynamic Information not present in EudraCT
    E.6.8Bioequivalence Information not present in EudraCT
    E.6.9Dose response Information not present in EudraCT
    E.6.10Pharmacogenetic Information not present in EudraCT
    E.6.11Pharmacogenomic Information not present in EudraCT
    E.6.12Pharmacoeconomic Information not present in EudraCT
    E.6.13Others Information not present in EudraCT
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E. trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.5The trial involves multiple Member States Yes
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months6
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero Information not present in EudraCT
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) Information not present in EudraCT
    F.1.1.3Newborns (0-27 days) Information not present in EudraCT
    F.1.1.4Infants and toddlers (28 days-23 months) Information not present in EudraCT
    F.1.1.5Children (2-11years) Information not present in EudraCT
    F.1.1.6Adolescents (12-17 years) Information not present in EudraCT
    F.1.2Adults (18-64 years) Yes
    F.1.3Elderly (>=65 years) Yes
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Information not present in EudraCT
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation Information not present in EudraCT
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state20
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 30
    F.4.2.2In the whole clinical trial 120
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Subjects who continue in the study until Visit 8/Week 14 will be offered the option to enter a long-term safety extension study (under a separate protocol) at that time.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2007-03-09
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2007-05-08
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice